Terumo (OTCMKTS:TRUMY) Shares Gap Up - Here's Why

Key Points

• Terumo Corporation shares increased, opening at $18.60 after a previous close of $17.85, reflecting a notable market movement.
• The company reported a $0.20 EPS for the quarter, exceeding analyst expectations of $0.17, despite revenues of $1.76 billion falling short of the consensus estimate of $1.80 billion.
• Terumo has a market capitalization of $26.68 billion and maintains strong liquidity ratios, with a current ratio of 2.64 and a quick ratio of 1.53.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $17.85, but opened at $18.60. Terumo shares last traded at $17.96, with a volume of 6,522 shares trading hands.

Terumo Stock Performance

The business's 50 day simple moving average is $17.57 and its 200 day simple moving average is $18.21. The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07. The company has a market cap of $26.68 billion, a P/E ratio of 31.61 and a beta of 0.79.

Terumo (OTCMKTS:TRUMY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. Terumo had a net margin of 12.09% and a return on equity of 9.19%. The business had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.80 billion.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.